Yung Shin Pharmaceutical Ind. Co., Ltd.

Yung Shin Pharm. Ind. Co., Ltd.

Yung Shin Pharmaceutical Industrial Co. Ltd.

Other

Yung Shin Pharma Ind. Co., Ltd.

Industrial Technology Research Institute

University of North Carolina at Chapel Hill

Carlsbad Technology, Inc.

Yung Shin Pharmaceuticals Industrial Co., Ltd

Fang-Yu Lee

Sheng-Chu Kuo

Che-Ming Teng

Shan-Chiung Chen

Shiow-Lin Pan

Jih-Hwa Guh

Chiung-Ju Tsai

Han-Chiang Kuo

Bin-Ken Chen

Li-Jiau Huang

Tsang-Miao Huang

Yen-Ling Yi

Anderson C Hong

Shan-chiung Chen

Ming-Liang Lee

Kuo-Hsiung Lee

Kenneth F Bastow

On Lee

Li-Chen Chou

Chrong-Shiong Hwang

Wen-Mei Fu

Chih-Hsin Tang

Chi-Ying Hung

Ping-Kuen Chen

Hironari Ohtsu

Rong-Sen Yang

Chao-Ho Chung

Yuka Nakanishi

Mei-Ling Shih

Fang-Chen Lee

Huan Wu

Fu-Yung Lin

Hua-Sin Chen

Ming Ching Chang

Yuan-Ken Lin

Schung-Ching Chiu

Chin-Yi Wu

Wei-Liang Lin

Houng-Chin Liou

Dah-Yuu Lu

A method of preparing a very slightly soluble drug with solid composition includes the following steps: (a) adding a very slightly soluble drug into an organic solvent and polysorbate to form a first solution; (b) adding the first solution into a second solution and a pharmaceutically acceptable excipient, wherein the second solution comprises water or SLS, and a volume ratio of the first solution and the second solution is between 8:1 and 1:1; and (c) drying and compressing the mixture in step (b) to form a very slightly soluble drug with solid composition.

Method of preparing very slightly soluble drug with solid dosage form

A fused pyrazolyl compound having an anti-tumor potency of the following formula is synthesized: wherein A is in which n is 0, 1, 2, or 3; Aris benzene, thiophene or furan; Aris furyl; and Aris phenyl; Rand Rindependently are hydrogen, halogen or &#x2014;(CH)OR; Ris hydrogen or alkyl; Ris &#x2014;(CH)-A, wherein r is an integer of 1-5, and Ahas a formula of &#x2014;O&#x2014;C(O)&#x2014;(CRH)&#x2014;NRR; Rand Rindependently are hydrogen, halogen, or alkyl, or Rand Rtogether are &#x2014;O(CH)O&#x2014;; Ris H, halogen, nitro, cyano, alkyl, or aryl; Ris H, alkyl, or aryl; Rand Rindependently are H, alkyl, or aryl; m is 0, 1, 2, 3, 4, 5, or 6; and q is 1, 2, 3, 4, 5, or 6; or a salt thereof.

Fused pyrazolyl compounds having an aminoalkylcarbonyl group

A method for preferentially inhibiting release of pro-inflammatory cytokines over release of anti-inflammatory cytokines using a fused pyrazolyl compound of formula (I): A is R or in which R is H, alkyl, aryl, cyclyl, heteroaryl, or heterocyclyl; each of Ar, Ar, and Ar, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R, R, R, R, R, and R, independently, is R', nitro, halogen, &#x2014;C(O)&#x2014;OR&#x2032;, &#x2014;C(O)&#x2014;SR&#x2032;, &#x2014;C(O)&#x2014;NR&#x2032;R&#x2033;, &#x2014;(CH)OR&#x2032;, &#x2014;(CH)SR&#x2032;, &#x2014;(CH)NR&#x2032;R&#x2033;, &#x2014;(CH)CN, &#x2014;(CH)C(O)&#x2014;OR&#x2032;, &#x2014;(CH)C(O)H, or Rand Rtogether, Rand Rtogether, or Rand Rtogether are &#x2014;O(CH2)O&#x2014;, in which each of R&#x2032; and R&#x2033;, independently, is H, alkyl, cyclyl, aryl, heteroaryl, heterocyclyl; and m is 0, 1, 2, 3, 4, 5, or 6; and n is 1, 2, or 3. This invention also covers a method of inhibiting activity of NF-&#x3ba;B with such a compound.

Preferential inhibition of release of pro-inflammatory cytokines

Novel compounds of 2-(substituted arylmethyl)-3-(substituted phenyl)-2H-indazoles and 1-(substituted arylmethyl)-3-(substituted phenyl)-1H-indazoles are synthesized, and useful as anti-angiogenic agents.

[object Object]

A fused pyrazolyl compound of the following formula: wherein A, Ar, Ar, R, R, R, and R, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective amount of the above-described fused pyrazolyl compound.

Fused pyrazolyl compound

The present invention provides an injectable pharmaceutical composition containing, as an active ingredient, paclitaxel, an anti-cancer agent. The injectable pharmaceutical composition comprises an effective amount of paclitaxel, which is dissolved in polyoxyethylated castor oil, alcohol, and an injectable aqueous solution. A sufficient amount of COis added to stabilize paclitaxel in the injectable pharmaceutical composition to make the injectable pharmaceutical composition to a pH about 5.0.

Paclitaxel aqueous injection solution and methods for preparing the same

Disclosed in this invention is a method of treating a disorder associated with low cGMP levels. The method includes administering to a subject in need thereof an effective amount of a compound having a pyrazolyl core, a first aryl group bonded to 3-C of the pyrazolyl core, and a second aryl group fused at 4-C and 5-C of the pyrazolyl core. Also disclosed are pharmaceutical compositions containing these compounds.

Treatment of disorder related to low cyclic GMP levels

The present invention provides two new microorganism strains of, designated as YS-44442 and YS-45494, a process of producing pravastatin using the strains, and an improved process for isolation of (HMG)-CoA reductase inhibitors.

The present invention synthesizes a series of novel indole analogs of 1-benzyl-3-(5'-hydroxymethyl-2&#x2032;-furyl)indazole (YC-1), and their anti-platelet activity.

Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethyl-2&#x2032;-furyl) indazole (YC-1) as anti-platelet agents

The present invention provides pharmaceutically acceptable salts having local anesthetic and anti-inflammatory activities. The preferred pharmaceutically acceptable salt is a diclofenac salt of lidocaine. Diclofenac is a non-steroidal anti-inflammatory drug ('NSAID'). Lidocaine is a local anesthetic. Other NSAID (except the salicylic acid derivatives of NSAID) can be used to replace diclofenac and/or other local anesthetics can be used to replace lidocaine. The pharmaceutically acceptable salts are crystalline compounds, which are distinctively different from either the NSAID alone or the local anesthetic alone, as indicated by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), High Performance Liquid Chromatography (HPLC) and Fourier-Transformed Infrared Spectroscopy (FTIR) analyses. These pharmaceutically acceptable salts are suitable for use in topical treatment or parenteral injection to treat patients with localized pain, including muscle pain, joint pain, pain associated with herpes infection, and wound pain (such as surgical wound, burn wound etc.).

Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same

This invention features a method for enhancing bone growth or inhibiting bone resportion. The method includes administering to a subject in need thereof a compound of the following formula: A is H, R, or each of Ar, Ar, and Ar, independently, is phenyl, thienyl, furyl, or pyrrolyl; each of R, R, R, R, R, and R, independently, is H, halogen, R, C(O)OH, C(O)OR, C(O)SH, C(O)SR, C(O)NH, C(O)NHR, C(O)NRR', ROH, ROR&#x2032;, RSH, RSR&#x2032;, NHR, NRR&#x2032;, RNHR&#x2032;, or RNR&#x2032;R&#x2033;; or Rand Rtogether, Rand Rtogether, or Rand Rtogether are ORO; wherein each of R, R&#x2032;, and R&#x2033;, independently is C&#x2dc;Calkyl; and n is 1, 2, or 3.

Method of increasing bone density or treating osteoporosis

The present invention provides a topical formulation containing NSAID, particularly diclofenac. The topical formulation is particularly useful for alleviating pain/inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Similar relief can be achieved where diclofenac is replaced with another non-steroidal anti-inflammatory drug (NSAID), which includes, without limitation, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, suprofen, meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, and tolmetin. The topical formulation is further characterized by its fast relief on pain and/or inflammation associated with infection caused by herpes virus, i.e., a complete relief in no more than seven (7) days after the application of the topical formulation on skins of patients.

Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection

The present invention features a method for treating sepsis. The method includes administrating to a subject in need thereof an effective amount of a fused pyrazolyl compound of formula (I):A is H, C&#x2dc;Calkyl, orin which n is 0, 1, 2, or 3; each of Ar, Ar, and Ar, independently, is phenyl, pyridinyl, thienyl, furyl, or pyrrolyl; and each of R, R, R, R, R, and R, independently, is XYZ; or Rand Rtogether, Rand Rtogether, or Rand Rtogether are O(CH)O; in which X is a bond or C&#x2dc;Calkylene, Y is a bond, O, S, OC(O), OC(O)(CH)C(O)O, C(O)O, C(O)S, C(O)NH, C(O)NC&#x2dc;Calkyl, NH, or NC&#x2dc;Calkyl, and Z is H, halogen, CN, NO, or C&#x2dc;Calkyl; and provided that one of Rand Ris not H.

Methods of treating sepsis

The present invention provides oral pharmaceutical compositions for acetic acid class of non-steroidal anti-inflammatory drug (NSAID), particularly ketorolac. The pharmaceutical composition contains a core, a drug layer (which comprises the drug, a binder, and a disintegrant), a protecting layer, and an enteric coating layer. The oral pharmaceutical compositons are particularly useful for treating patients with moderate to acute pain. The present invention also provides a method for making the pharmaceutical compositions and a method for using the pharmaceutical compositions.

Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same

The present invention provides two new microorganism strains of Saccharothrix, designated as YS-44442 and YS-45494, a process of producing pravastatin using the strains, and an improved process for isolation of (HMG)-CoA reductase inhibitors.

Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase

Growing community of inventors

Taichung, Taiwan

Fang-Yu Lee